Mark O'Herlihy explains how and why machine learning will be fundamental to the healthcare of tomorrow, admitting that there is still a great deal of work to be done to demystify the role of new technologies by identifying proven results and best practice.
“We are years ahead of any competitor that may appear in the future,” says Claudia Jimenez, General Manager of biotech company ALGENEX, which uses moths to develop vaccines.
Stephan Sturm, Global CEO of Fresenius Group, says that we are fast approaching a new world of care, with a much stronger focus on prevention and more personalised treatment pathways.
Micro-immunotherapy can be used as supportive therapy for diseases which are the consequence of an imbalance in the immune system and has far fewer side effects than other treatments, explains Ian Wilders, Labo’Life’s Group CEO.
Mark Ware, Chief Medical Officer at Canopy Growth Corporation, shares his vision for the future of the medical cannabis sector and says there is massive patient demand; however, research and clinical trials have yet to catch up to position cannabis as a respected medical product.